Anika Therapeutics, Inc.
ANIK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -0.7% | 6.1% | -23% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 63.4% | 68.3% | 64.3% | 56.1% |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 2.5% | 12.5% | 16% | -2.8% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -47% | -68.4% | -13.1% | 2.8% |
| EPS Diluted | -3.83 | -5.64 | -1.02 | 0.28 |
| % Growth | 32.1% | -452.9% | -464.3% | – |
| Operating Cash Flow | $0 | -$0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |